Why Measles Is Re‑Appearing in the U.S.: Key Trends to Watch Recent clusters of measles cases have reminded us that the disease is not a relic of the past. While the United States declared measles eliminated in 2000, growing pockets of under‑immunized communities are creating conditions for renewed transmission. 1. Declining School Vaccination Rates Nationwide, … Read more
Why Circular Single‑Stranded DNA Is Poised to Transform Gene Therapy Traditional gene‑editing tools rely on viral vectors or double‑stranded DNA (dsDNA). Both trigger immune responses and struggle with efficient packaging, limiting the reach of next‑generation medicines. Circular single‑stranded DNA (cssDNA) sidesteps these hurdles: it is less immunogenic, more stable than RNA, and can be engineered … Read more
Why Europe’s NCD Monitoring Must Evolve — And What That Means for the Next Decade Non‑communicable diseases (NCDs) still claim more lives in Europe than any other health threat. As the Lancet Regional Health—Europe paper warns, the continent’s current monitoring systems are fragmented, under‑funded, and often blind to the most vulnerable. The five priority actions outlined by … Read more
Why Normalising Blood Glucose Could Become the Next “Big Four” of Heart‑Health Prevention Recent analyses of the US Diabetes Prevention Program Outcomes Study (DPPOS) and the Chinese DaQingDPOS have shown that reversing pre‑diabetes – that is, bringing fasting glucose back into the normal range – slashes the risk of cardiovascular death by more than 50 %. … Read more
Why Omisirge Is a Game‑Changer for Severe Aplastic Anemia When the FDA green‑lighted Omisirge (omidubicel‑onlv) as the first approved hematopoietic stem‑cell transplant (HSCT) for severe aplastic anemia (SAA), it signaled a new era for cellular therapies. By chemically enhancing donated cord‑blood stem cells with nicotinamide, the treatment accelerates neutrophil engraftment and reduces infection risk—a critical … Read more
Rethinking Menopausal Hormone Therapy for Women with BRCA Mutations Women who carry a pathogenic BRCA1 or BRCA2 variant face a unique set of challenges after prophylactic oophorectomy. While the surgery dramatically cuts ovarian‑cancer risk, it also triggers abrupt surgical menopause, often in the early 40s. Historically, National Cancer Institute guidelines have warned that menopausal hormone … Read more
What’s on the Horizon for Adult‑Onset Still’s Disease (AOSD) Management? Since the EULAR Points to Consider were released, clinicians have a clearer roadmap for measuring disease activity in AOSD. But the journey doesn’t stop at consensus statements. Emerging technologies, novel biomarkers, and patient‑centered tools are poised to reshape how we define flare, remission, and treatment … Read more
Why Demographic Data in Electronic Health Records Is the Engine of Future Health Innovation Every time you answer a question about race, marital status, or housing during a clinic visit, you’re feeding a data stream that powers tomorrow’s predictive analytics and AI‑driven care pathways. While the questions can feel intrusive, the information helps researchers uncover … Read more
The Longevity Revolution: Beyond Lifespan to ‘Healthspan’ For decades, the pursuit of a longer life has captivated scientists and the public alike. But a subtle yet profound shift is underway: the focus is no longer simply *how long* we live, but *how well*. This is the era of ‘healthspan’ – the period of life spent … Read more
The Shadow of Kjeld: How a Genetic Mutation in Sperm Donation is Reshaping Reproductive Ethics The recent revelation that a Danish sperm donor, known only as Kjeld, fathered nearly 200 children worldwide while carrying a cancer-linked genetic mutation has sent ripples through the fertility industry. This isn’t simply a story about one donor; it’s a … Read more